John "Lippy" Lippincott, PhDVice President of Research at AlivaMab Discovery Services
Lippy joined Ablexis in 2012 as director of research operations, where he built the processes and team responsible for the data package validating the AlivaMab Mouse. He currently serves as consultant to Ablexis and is vice president of research at AlivaMab Discovery Services. Lippy has nearly two decades of experience in the generation and characterization of antibodies from in vivo systems.
Prior to joining Ablexis, Lippy established and led the hybridoma group at Pfizer’s San Diego site, where he was project leader for internal and co-development therapeutic discovery projects. At Igenica, he led the successful importation of a novel in vivo discovery platform and created a high-throughput system for hybridoma generation and screening, and led other processes required for identifying lead therapeutic candidates. Serving in the role of vice president, antibody discovery at LakePharma, Lippy built and led the team responsible for providing antibody discovery services to clients. Lippy received his Ph.D. from Harvard University and did postdoctoral research at the Genomics Institute of the Novartis Research Foundation in San Diego.